Regulatory T cells: A new frontier in cancer immunotherapy

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 255-260

  Barnett, Brian G ^a   Rüter, Jens ^a   Kryczek, Ilona ^a   Brumlik, Michael J ^a   Cheng, Pui Joan ^a   Daniel, Benjamin J ^a   Coukos, George ^a   Zou, Weiping ^a   Curiel, Tyler J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; FLUDARABINE; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; VASCULOTROPIN;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; MOUSE; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE DRUG DOSE; T CELL LEUKEMIA; T CELL LYMPHOMA; THERAPY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGY; IMMUNOTHERAPY; METHODS; NEOPLASMS; T-LYMPHOCYTES, REGULATORY; THERAPY;

EID: 84934444227     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_20     Document Type: Review

References (24)

1. Prehn, R. (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18, 769.
2. Curiel, T.J. et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-949.
3. Curiel, T.J. et al. (2003) Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 9, 562-567.
4. Zou, W. et al. (2001) Reciprocal regulation of plasmacytoid dendritic cells and monocytes during viral infection. Eur J Immunol 31, 3833-3839.
5. Zou, W. (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5, 263-274.
6. Zou, W. (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev 6, 295-307.
7. Shevach, E.M. (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev2, 389-400.
8. Francois Bach, J. (2003) Regulatory T cells under scrutiny. Nat Rev 3, 189-198.
9. Shimizu, J. et al. (1999) Induction of tumor immunity by removing CD25 + CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163, 5211-5218.
10. Sutmuller, R.P. et al. (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194, 823-832.
11. Steitz, J. et al. (2001) Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinaserelated protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 61, 8643-8646.
12. Woo, E.Y. et al. (2001) Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61, 4766-4772.
13. Woo, E.Y. et al. (2002) Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 168, 4272-4276.
14. Javia, L.R., and Rosenberg, S.A. (2003) CD4 + CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26, 85-93.
15. Somasundaram, R. et al. (2002) Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-beta. Cancer Res 62, 5267-5272.
16. Wolf, A.M. et al. (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9, 606-612.
17. Sasada, T. et al. (2003) CD4 + CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 98, 1089-1099.
18. Liyanage, U.K. et al. (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol169, 2756-2761.
19. Zou, W. et al. (2001) Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 7, 1339-1346.
20. Foss, F.M. (2000) DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 1, 110-116; discussion 117.
21. Wei, S. et al. (2005) Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma". Cancer Res 65, 5020-5026.
22. Almand, B. et al. (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166, 678-689.
23. Taniguchi, M. et al. (2003) The regulatory role of Valpha14 NKT cells in innate and acquired immune response. Annu Rev Immunol 21, 483-513.
24. Kryczek, I. et al. (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203, 871-881.